FDA
-
-
-
-
-
-
-
LivaNova (LIVN) Delivers Strategic Roadmap and Long-Range Financial Plan at Investor Day
-
-
-
-
-
-
-
LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance
-
-
-
-
-
-
-
LivaNova Provides Update on RECOVER Clinical Study Evaluating VNS Therapy for Treatment-Resistant Depression in Unipolar Patients
-
-
-
-
-
-
-
LivaNova Unveils Essenz In-Line Blood Monitor with U.S. FDA 510(k) Clearance and CE Mark
-
-
-
-
-
-
-
LivaNova Launches SenTiva DUO
-
-
-
-
-
-
-
LivaNova Reports First-Quarter 2022 Results
-
-
-
-
-
-
-
LivaNova Receives FDA Approval for Clinical Study to Evaluate the aura6000 System to Treat Obstructive Sleep Apnea
-
323,119 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

